Multiple Sclerosis Clinical Trials

Showing 881-900 of 5,960 trials

PC001- A Study to Evaluate the Usability of PointCheck

NCT04448301

This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia. The study will include patients with cancer visiting the outpatient hematology clinic for their standard of care chemotherapy administration. A final sample size of 90 oncologic outpatients will be enrolled and studied with the technology. The main objective is to evaluate the usability of PointCheck. Secondary outcomes include a preliminary assessment of PointCheck diagnostic accuracy and precision. For this, study subjects will be tested twice with PointCheck during the same session and the usability in an at-home simulated environment by naïve users will be evaluated

NeoplasmsNeutropenia

Leuko Labs, Inc.81 participantsStarted Feb 2021

Boston, Massachusetts, United States

COMPLETEDPhase 1

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

NCT03396445

The purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults. Boserolimab monotherapy or boserolimab plus pembrolizumab combination therapy will be administered in adults with advanced solid tumors, including endometrial cancer, for up to 35 administrations (approximately 2 years). The safety and pharmacokinetics of boserolimab when administered with pembrolizumab, pemetrexed and carboplatin in adults with non-squamous non-small cell lung cancer (NSCLC) and boserolimab when administered with pembrolizumab and nab-paclitaxel in adults with triple-negative breast cancer (TNBC) will also be assessed.

PharmacokineticsSolid TumorCarcinoma, Non-Small-Cell Lung+1 more

Merck Sharp & Dohme LLC182 participantsStarted Feb 2018

Mobile, Alabama, United States • Sarasota, Florida, United States • Germantown, Tennessee, United States +15 more locations

PC001- A Study to Evaluate the Usability of PointCheck

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Related Searches

RXWell to Decrease Post-Operative Opioid Use in Total Knee or Hip Arthroplasty

Mood and Thought Process Study

Evaluation of Teen Connection Project for Trans and Gender Minority Youth

Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

Effects of Cycling and Virtual Reality on Thinking Speed in Persons With MS (PACE-MS)

HOBSCOTCH-MS-Efficacy Trial

TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

BabyStrong Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Paired Bottle Feeding to Improve Oral Feeding

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Mobile Web-based Behavioral Intervention for Improving Caregiver Well-being

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)